June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Ophthalmological manifestations in type 2 neurofibromatosis
Author Affiliations & Notes
  • Mardoche Chetrit
    Ophthalmology Department, Vision and Handicaps DHU, Pitie Salpetriere Hospital, Paris, France
  • Georges Challe
    Ophthalmology Department, Vision and Handicaps DHU, Pitie Salpetriere Hospital, Paris, France
  • Michel Kalamarides
    Neurosurgery Department, Pitie Salpetriere Hospital., Paris, France
  • Nathalie Massamba
    Ophthalmology Department, Vision and Handicaps DHU, Pitie Salpetriere Hospital, Paris, France
  • Valerie Touitou
    Ophthalmology Department, Vision and Handicaps DHU, Pitie Salpetriere Hospital, Paris, France
  • Bahram Bodaghi
    Ophthalmology Department, Vision and Handicaps DHU, Pitie Salpetriere Hospital, Paris, France
  • Phuc LeHoang
    Ophthalmology Department, Vision and Handicaps DHU, Pitie Salpetriere Hospital, Paris, France
  • Footnotes
    Commercial Relationships Mardoche Chetrit, None; Georges Challe, None; Michel Kalamarides, None; Nathalie Massamba, None; Valerie Touitou, None; Bahram Bodaghi, None; Phuc LeHoang, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5988. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Mardoche Chetrit, Georges Challe, Michel Kalamarides, Nathalie Massamba, Valerie Touitou, Bahram Bodaghi, Phuc LeHoang; Ophthalmological manifestations in type 2 neurofibromatosis. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5988.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Type 2 neurofibromatosis (NF2) is a rare and serious genetic disease characterized by the development of multiple nervous tumors. Ophthalmologic manifestations are frequent and can sometimes suggest the diagnosis of NF2 before the genetic results. The aim of this prospective series of cases is to evaluate the type and prevalence of ophthalmological manifestations in NF2.

Methods: Patients with genetically confirmed NF2 seen in the Ophthalmology department from a single tertiary center, in collaboration with the NF2 international reference center between November 2013 and November 2014 were prospectively included. For each patient, the best corrected visual acuity (BCVA), oculomotricity examination, slit lamp examination, fundus examination and macular SD-OCT were performed.

Results: 47 patients (30W/17M) were included in the study. Mean age was 34.3 years old (range: 14-70). 45% of patients had a significantly decreased visual acuity (VA) on at least on eye (0.5 logMar), with an average VA of 0.31 logMar. 40% of patients had a significant cataract, 26% of patients presented an exposure keratitis due to facial nerve paresis and 21% of patients had an optic disc atrophy. In 43% of patients, an oculomotor disorder was observed. An epiretinal membrane (ERM) was diagnosed on SD-OCT in 64% of patients.

Conclusions: Visual impairment in type 2 neurofibromatosis is frequent and mostly related to optic nerve atrophy or exposure keratitis. Cataract and ERM were non-symptomatic in most patients, but these latter can guide the diagnosis if the suspicion is high. We report the largest prospective series of ocular manifestations in NF2. The impairment of the visual function is multi-factorial and all the more disabling as it occurs in patients whose sensory perception is often already impaired by a lesion of the 8th cranial nerve.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×